New-Onset Atrial Fibrillation After Exenatide Injection: Coincidence or Consequence?

Abstract

The glucagon-like peptide 1 receptor agonists, together with sodium-glucose cotransporter-2 inhibitors, are antidiabetic drugs known for their beneficial effects on the cardiovascular system; many phase 3 trials also support this conclusion. However, it can be thought that they may cause an increase in the risk of tachyarrhythmia due to the stimulation of their receptors in the sympathetic nervous system and sinoatrial cells. We report a case of a 71-year-old woman with no history of arrhythmia who presented with new-onset atrial fibrillation after an exenatide injection during clinical follow-up.

Cite this article as: Yamantürk YY, Esenboğa K, Yılmaz GC, Baskovski E, Candemir B, Şahin M. New-onset atrial fibrillation after exenatide injection: Coincidence or consequence? Endocrinol Res Pract. 2023;27(4):241-244.